{
  "model": "gemini-3.1-pro-preview",
  "agentReasoning": "medium",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "workspacePath": "workspaces/gemini-3-1-pro-preview-tumor-vaccine-ici-run-1",
  "success": false,
  "schemaPass": true,
  "toolTracePass": true,
  "graderPass": false,
  "durationMs": 138342,
  "agentCostUsd": 0.162052,
  "graderCostUsd": 0,
  "totalCostUsd": 0.162052,
  "agentUsage": {
    "promptTokens": 14834,
    "cachedTokens": 0,
    "responseTokens": 2897,
    "thinkingTokens": 8135,
    "totalTokens": 25866
  },
  "graderUsage": {
    "promptTokens": 0,
    "cachedTokens": 0,
    "responseTokens": 0,
    "thinkingTokens": 0,
    "totalTokens": 0
  },
  "totalUsage": {
    "promptTokens": 14834,
    "cachedTokens": 0,
    "responseTokens": 2897,
    "thinkingTokens": 8135,
    "totalTokens": 25866
  },
  "modelVersions": [
    "gemini-3.1-pro-preview"
  ],
  "agentFinalText": "All required data has been drafted and written successfully.\n\n**Checklist of written output files:**\n- [x] `output/study_overview.json`\n- [x] `output/quantitative_findings.json`\n- [x] `output/claim_audit.json`\n- [x] `output/public_summary.json`",
  "outputValidation": [
    {
      "outputFile": "output/study_overview.json",
      "schemaFile": "schemas/study_overview.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy\",\n      \"label\": \"Mouse efficacy cohort\",\n      \"sample_size_or_observations\": \"78\",\n      \"description\": \"Tumor-bearing mice pooled across repeat experiments for combination therapy.\"\n    },\n    {\n      \"id\": \"mouse-control\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84\",\n      \"description\": \"Tumor-bearing mice pooled across matched controls including vaccine only, ICI only, and vehicle.\"\n    },\n    {\n      \"id\": \"human-retro\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130\",\n      \"description\": \"Total number of patients in the retrospective human metastatic cohort.\"\n    },\n    {\n      \"id\": \"human-vaccinated\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43\",\n      \"description\": \"Patients in the human retrospective cohort who were vaccinated.\"\n    },\n    {\n      \"id\": \"human-unvaccinated\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87\",\n      \"description\": \"Patients in the human retrospective cohort who were unvaccinated.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n  ]\n}"
    },
    {
      "outputFile": "output/quantitative_findings.json",
      "schemaFile": "schemas/quantitative_findings.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\n        \"L28\"\n      ]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\n        \"L29\"\n      ]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\n        \"L30\"\n      ]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\n        \"L31\"\n      ]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\n        \"L32\"\n      ]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\n        \"L33\"\n      ]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/claim_audit.json",
      "schemaFile": "schemas/claim_audit.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination effectively triggers local type I interferon signaling.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"mRNA vaccination broadens the tumor immunopeptidome and MHC-I presentation.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\",\n          \"line_ref\": \"L29\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"mRNA vaccination improves subsequent sensitivity to checkpoint blockade therapies.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\",\n          \"line_ref\": \"L33\"\n        },\n        {\n          \"quote\": \"5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Human patients with prior mRNA vaccination have improved outcomes under ICI therapy.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"- The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        }\n      ],\n      \"caveat\": \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/public_summary.json",
      "schemaFile": "schemas/public_summary.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"headline\": \"SARS-CoV-2 mRNA Vaccines Show Potential to Make Tumors More Responsive to Immunotherapy\",\n  \"plain_language_summary\": \"Immunotherapy works well for some cancers but fails in others because the tumors are able to hide from the immune system. This study investigated whether injecting an mRNA vaccine directly into tumors could act like a flare, alerting the immune system and creating an inflammatory state. The researchers found that mRNA vaccines triggered an immune reaction, expanding the number of targets displayed on the tumor surface. This made the tumors significantly more susceptible to subsequent immune checkpoint blockade therapies in mouse models. The researchers also observed that among human metastatic cancer patients, those who had received an mRNA vaccination showed better survival rates when treated with immunotherapy, although this finding is preliminary and requires further randomized clinical trials.\",\n  \"what_is_new\": [\n    \"Intratumoral injection of mRNA vaccines can trigger beneficial local type I interferon signaling in tumors.\",\n    \"The mRNA vaccine expands the landscape of tumor antigens presented by MHC-I molecules.\",\n    \"Both mouse models and human retrospective data point to a synergistic effect when combining mRNA vaccines with anti-PD-L1 checkpoint inhibitors.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human data is retrospective and non-randomized, meaning other factors could have influenced patient survival.\",\n    \"The timing of vaccination relative to starting immunotherapy varied among patients, complicating interpretations.\",\n    \"Some mechanistic responses were only seen strongly in specific animal models, rather than universally across all types of cancer.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitors\",\n      \"definition\": \"A type of cancer immunotherapy that blocks proteins that stop the immune system from attacking the cancer cells.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The complete set of protein fragments (peptides) displayed on the surface of cells, which the immune system uses to recognize threats.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"Proteins produced by host cells in response to pathogens that help regulate the activity of the immune system.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"Major histocompatibility complex class I molecules, which display protein fragments from inside the cell onto the cell surface for T cells to inspect.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will these findings hold true in large-scale, prospective randomized clinical trials?\",\n    \"Which specific types of tumors are most likely to benefit from this combination therapy approach?\",\n    \"What is the optimal timing and dosing schedule for mRNA vaccination relative to immune checkpoint blockade?\"\n  ]\n}"
    }
  ],
  "toolTrace": {
    "pass": true,
    "totalCalls": 20,
    "failedCalls": 0,
    "toolsUsed": [
      "read_file",
      "write_file"
    ],
    "hasSuccessfulRead": true,
    "hasSuccessfulWrite": true,
    "pathPolicyViolations": [],
    "notes": [],
    "calls": [
      {
        "source": "llm",
        "step": 1,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "write_file"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "TASK.md",
        "timestamp": "2026-02-19T17:19:59.545Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "input/report.md",
        "timestamp": "2026-02-19T17:20:03.416Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/study_overview.schema.json",
        "timestamp": "2026-02-19T17:20:03.416Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/quantitative_findings.schema.json",
        "timestamp": "2026-02-19T17:20:03.417Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/claim_audit.schema.json",
        "timestamp": "2026-02-19T17:20:03.417Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/public_summary.schema.json",
        "timestamp": "2026-02-19T17:20:03.417Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-19T17:22:07.282Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-19T17:22:07.282Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-19T17:22:07.282Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-19T17:22:07.283Z"
      }
    ]
  },
  "grader": {
    "model": "chatgpt-gpt-5.2",
    "error": "LLM JSON call failed after 2 attempt(s)"
  }
}
